NUFYMCO® (biosimilar ranibizumab)

About Polpharma Biologics

Polpharma Biologics, originally founded in 2012 and headquartered in the Netherlands, has undergone a significant transformation, splitting into two independent entities. The remaining Polpharma Biologics is now a pure-play biosimilars developer with a strategic base in Zug, Switzerland, focusing on building a targeted pipeline and forging global partnerships. The company has a commercial-stage asset, Tyruko®, and leverages an agile development model aimed at accelerating biosimilar approval and market access. Its former large-scale manufacturing and CDMO operations now reside with the separate company, Rezon Bio, based in Poland.

Therapeutic Areas